2022
Ketamine use in pediatric depression: A systematic review
Meshkat S, Rosenblat J, Ho R, Rhee T, Cao B, Ceban F, Danayan K, Chisamore N, Vincenzo J, McIntyre R. Ketamine use in pediatric depression: A systematic review. Psychiatry Research 2022, 317: 114911. PMID: 37732856, DOI: 10.1016/j.psychres.2022.114911.Peer-Reviewed Original ResearchConceptsSafety of ketamineRandomized clinical trialsPediatric depressionIntravenous ketamineNon-competitive N-methyl-D-aspartate (NMDA) receptor antagonistN-methyl-D-aspartate receptor antagonistSystematic reviewOpen-label trialSevere adverse eventsCommon psychiatric disordersDifferent administration modalitiesAdverse eventsAntidepressant effectsSignificant morbidityMean ageCase reportReceptor antagonistClinical trialsAdministration modalitiesDepressive symptomsPsychiatric disordersKetamine useElectronic databasesLarger sample sizeKetamine
2020
Estimated Proportions and Characteristics of National Survey Respondents Reporting New Diagnoses of Schizophrenia or Other Psychoses in the Past Year as Compared With Prior Years.
Bommersbach T, Rhee TG, Stefanovics E, Rosenheck R. Estimated Proportions and Characteristics of National Survey Respondents Reporting New Diagnoses of Schizophrenia or Other Psychoses in the Past Year as Compared With Prior Years. The Journal Of Nervous And Mental Disease 2020, 209: 65-70. PMID: 33141782, DOI: 10.1097/nmd.0000000000001259.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersEarly psychosisPast-year substance use disorderInfrequency of casesFirst-time diagnosisFirst-episode psychosisPopulation-based estimatesNational Epidemiologic SurveyAlcohol use disorderRelated Conditions-IIINational survey respondentsMean ageEpidemiologic dataGeneral populationNew diagnosisEpidemiologic SurveyOlder populationPrevious yearPsychosisSchizophreniaPast yearDiagnosisDisordersSimilar elevations